Log In
BCIQ
Print this Print this
 

Biosimilar adalimumab (MSB11022)

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionBiosimilar of adalimumab, a human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe chronic plaque psoriasis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today